Intestinal epithelial barrier dysfunction in Crohn's disease

Proceedings of the Society for Experimental Biology and Medicine

Volumn 214, Issue 4, 1997, Pages 318-327

  Ma, Thomas Y ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EDETATE CHROMIUM CR 51; LACTULOSE; MACROGOL 400; MANNITOL; NONSTEROID ANTIINFLAMMATORY AGENT;

CROHN DISEASE; HUMAN; HYPOTHESIS; INFLAMMATION; INTESTINE EPITHELIUM; INTESTINE MUCOSA PERMEABILITY; RELATIVE; REVIEW;

EID: 0030958528     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-214-44099     Document Type: Review

References (87)

1. Lashner BA. Clinical feature, laboratory findings, and course of Crohn's disease. In: Kirsner JB, Shorter RG, Eds. Inflammatory Bowel Disease (4th ed). Baltimore: Williams and Wilkins, pp344-354, 1985.
2. Mayberry JF, Rhodes J. Epidemiological aspect of Crohn's disease: A review of the literature. Gut 25:886-899, 1984.
3. Serlin SM, Benkof KJ, Kazlow P, Dolgin S, Dische MR, LeLeiko NS. Occurrence of Crohn's disease in twins. J Clin Gastroenterol 8:290-294, 1986.
4. Farmer RC, McConnell RB. Familial inflammatory bowel disease-heredity of environment? Gut 17:235-243, 1976.
5. Pearson AD, Eastman EJ, Laker MF, Craft AW, Nelson R. Intestinal permeability in children with Crohn's disease and coeliac disease. Br Med J 285:20-21, 1982.
6. Ukabam SO, Clamp JR, Cooper BT. Abnormal small intestinal permeability to sugars in patients with Crohn's disease of the terminal ileum and colon. Digestion 27:74, 1983.
7. Bjarnason I, O'Morain C, Levi AJ, Peters TJ. Absorption of 51-chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 5:318-322, 1983.
8. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty TJ, Rotter JI. Increased intestinal permeability in patients with Crohn's disease and their relatives. Ann Intern Med 105:883-885, 1986.
9. Teahon K, Smethurst P, Lewi AJ, Menzies IS, Bjarnason I. Intestinal permeability in patients with Crohn's disease and their first degree relatives. Gut 33:320-323, 1992.
10. Katz KD, Hollander D, Vadheim CM, McElree C, Delahunty T, Dadufalza D, Krugliak P, Rotter JI. Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 97:927-931, 1989.
11. May GR, Sutherland LM, Meddings JB. Lactulose/mannitol permeability is increased in relatives of patients with Crohn's disease. Gastroenterology 102:A934, 1992.
12. Hollander D. The intestinal permeability barrier. A hypothesis as to its regulation and involvement in Crohn's disease. Scand J Gastroenterol 27:721-726, 1992.
13. Hollander D. Crohn's disease - A permeability disorder of the tight junction? Gut 29:1621-1624, 1988.
14. Csasky TZ. Intestinal permeation and permeability, an overview. Handbook Exp Pharmacol 70:51-9, 1987.
15. Chadwick VS, Phillips SF, Hofmann AF. Measurements of intestinal permeability using low molecular weight polyethylene glycol (PEG 400) II. Application to normal and abnormal permeability states in man and animals. Gastroenterology 73:247-251, 1977.
16. Anonymous. Intestinal permeability. (editorial) Lancet i:256-258, 1985.
17. Madara JL. Loosening tight junction lessons from the intestine. J Clin Invest 83:1089-1094, 1989.
18. Krugliak P, Hollander D, Ma TY, Tran D, Dadufalza VD, Katz KD, LeK. Mechanisms of polyethylene glycol 400 permeability in perfused rat intestine. Gastroenterology 97:1164-1170, 1989.
19. Ma TY, Hollander D, Krugliak P, Truong H. Is the small intestinal tight junctions truly "tight" to inulin permeation. Am J Physiol 260:G669-G676, 1991.
20. Hollander D, Koyama S, Dadufalza V, Tran DQ, Krugliak P, Ma TY, Ling KY. Polyethylene glycol 900 permeability of rat intestinal and colonic segments in in-vivo and brush border membrane vesicles in vitro. J Lab Clin Med 113:505-515, 1989.
21. Krugliak P, Hollander D, Schlaepfer CC, Nguyen H, Ma TY. Mechanism and sites of mannitol permeability of small and large intestine in the rat. Dig Dis Sci 38:796-801, 1994.
22. Krugliak P, Hollander D, Le K, Ma TY, Dadufalza VD, Katz KD. Regulation of polyethylene glycol 400 intestinal permeability by endogenous and exogenous prostanoids. Influence of non-steroidal anti-inflammatory drugs. Gut 31:417-421, 1990.
23. Claude P. Morphological factors influencing transepithelial permeability: A model for the resistance of the zonula occludens. J Membr Biol 39:219-232, 1978.
24. Madara JL, Dharmsathaphorn K. Occluding junction structure-function relationships in a cultured epithelial monolayer. J Cell Biol 101:2124-2133, 1986.
25. Marcial MA, Carlson SL, Madara JL. Partitioning of paracellular conductance along the ileal crypt-villus axis: A hypothesis based on structural analysis with detailed consideration of tight junction-structure function relationships. J Membr Biol 80:59-70, 1984.
26. Bjarnason I, Ward K, Peters TJ. The leaky gut of alcoholism; possible route of entry for toxic compounds. Lancet 1:179-182, 1984.
27. Triadafilopoulos S, Pothoulakis, O'Brien MJ, LaMont JT. Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology 93:273-279, 1987.
28. Atisook K, Carlson S, Madara JL. Effects of phlorizin and sodium on glucose-elicited alterations of cell junctions in intestinal epithelia. Am J Physiol 258:C77-C85, 1990.
29. ++ regulation of tight junction permeability and structure in Necturus gallbladder. Am J Physiol 245:C203-C212, 1983.
30. Madara JL, Stafford J. Interferon-γ directly affects barrier function of cultured intestinal epithelial monolayers J Clin Invest 30:724-735, 1989.
31. Ma TY, Tran LT, Hoa N, Bhalla D. Cytoskeletal regulation of Caco-2 intestinal monolayer paracellular permeability. J Cell Physiol 164:533-545, 1995.
32. Ma TY, Hoa N, Nguyen D. Effect of ethanol on paracellular permeability of Caco-2 intestinal epithelial monolayers. Gastroenterol 108:A867, 1995.
33. Madara JL, Barenberg D, Carlson S. Effects of cytochalasin D on occluding junctions of intestinal absorptive cells. Further evidence that cytoskeleton may influence paracellular permeability. J Cell Biol 97:2125-2135, 1986.
34. Grybovski JD, Thayer WR, Gabrielsson IW, Spiro HM. Disacchariduria in gastrointestinal disease. Gastroenterology 45:633-637, 1963.
35. Magnusson KE, Sundqvit T, Sjodahl R, Tagesson C. Altered intestinal permeability to low-molecular weight polyethyleneglycols (PEG 400) in patients with Crohn's disease. Acta Chir Scand 149:323-327, 1983.
36. Peled Y, Watz C, Gilat T. Measurement of intestinal permeability using 51Cr-EDTA. Am J Gastroenterol 80:770-773, 1985.
37. Olaison G, Sjodahl R, Tagesson C. Decreased gastrointestinal absorption of peroral polyethyleneglycols (PEG 1000) in Crohn's disease. Acta Chir Scand 153:373-377, 1987.
38. Sanderson IR, Boulton P, Menzies I, Walker-Smith JA. Improvement of abnormal lactulose/rhamnose permeability in active Crohn's disease of the small bowel by an elemental diet. Gut 28:1073-1076, 1987.
39. 51Cr-EDTA in patients with active inflammatory bowel disease. Clin Invest Med 11:151-155, 1988.
40. Andre F, Andre C, Emery Y, Forichon J, Descos L, Minaire Y. Assessment of the lactulose-mannitol test in Crohn's disease. Gut 29:511-515, 1988.
41. Andre F, Andre C, Emery Y, Forichon J, Descos L. Assessment of the lactulose-mannitol test in Crohn's disease, gut 29:511-515, 1988.
42. 51Cr-labeled ethylenediaminetetraacetic acid in patients with Crohn's disease and their healty relatives. Scand J Gastroenterol 24:993-998, 1989.
43. 51Cr-EDTA and inflammatory activity in asymptomatic patients with Crohn's disease. Dig Dis Sci 35:582-588, 1990.
44. Resnick RH, Royal H, Marshall W, Barron R, Werth T. Intestinal permeability in gastrointestinal disorders. Dig Dis Sci 35:205-211, 1990.
45. Howden CW, Robertson C, Duncan A, Morris AJ, Russell RI. Comparison of different measurements of intestinal permeability in inflammatory bowel disease. Am J Gastroenterol 86:1445-144, 1991.
46. Issenman RM, Jenkins RT, Radoja C. Intestinal permeability compared in pediatric and adult patients with inflammatory bowel disease. Clin Invest Med 16:187-196, 1992.
47. Adenis A, Colombel JF, Lecouffe P, Wallaert B, Hecquet B, Marchandise X, Cortot A. Increased pulmonary and intestinal permeability in Crohn's disease. Gut 33:678-682, 1992.
48. Ruttenberg D, Young Go, Wright JP, Isaacs S. PEG-400 excretion in patients with Crohn's disease, their first degree relatives, and healthy volunteers. Dig Dis Sci 37:705-708, 1992.
49. Kuiper S, Van Pelt J, Verheesen PE, Rentsch HU, Stockbrugger R, Van Der Linden SM. Patients with ankylosing spondylitis and healthy relatives do not show increased small intestinal permeability with lactulose-mannitol test. Clin Exp Rheum 11:413-416, 1993.
50. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 341:1437-1439, 1993.
51. May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn's disease? Gastroenterology 104:1627-1632, 1993.
52. Munkholm P, Langholz E, Hollander D, Thornberg K, Orholm M, Katz KD, Binder V. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut 35:68-72, 1994.
53. Cobden I, Rothwell J, Axon ATR. Intestinal permeability and screening tests for coeliac disease. Gut 21:512-518, 1980.
54. Hollander D, Ricketts D, Boyd CAR. The importance of "probe" molecular geometry in determining intestinal permeability. Can J Gastroenterol 235a-38a, 1988.
55. Ma TY, Hollander D, Nguyen H, Bhalla D, Krugliak P. IEC-18, a non-transformed small intestinal cell line for studying epithelial permeability. J Lab Clin Med 120:329-341, 1992.
56. Wyatt J, Vogelsang H, Lochs H. Effect of corticosteroids on intestinal permeability in patients with active Crohn's disease. Gastroenterology 102:A947, 1992.
57. + B cells in Crohn's disease correlates with intestinal permeability. Gastroenterology 108:132-137, 1995.
58. Falchuk KR, Isselbacher KJ. Circulating antibodies to bovine albumin in ulcerative colitis and Crohn's disease. Gastroenterology 70:5-8, 1976.
59. Fiasse R, Lurhuma AZ, Cambiaso CJ. Mazsson PL, Dive C. Circulating immune complexes and disease activity in Crohn's disease.Gut 19:611-617, 1978.
60. Hodgson HJF, Potter BJ, Jewell DP. Immune complexes in ulcerative colitis and Crohn's disease. Clin Exp Immunol 29:187-196, 1977.
61. Ambrose NS, Johnson M, Burdon DW, Keighley MRB. Incidence of pathogenic bacteria from mesenteric lymph nodes and ileal serosa during Crohn's disease surgery. Br J Surg 71:623-635, 1984.
62. Auer IO, Rider A, Wensinck F, Van de Merve JP, Schmidt H. Selected bacterial antibodies in Crohn's disease and ulcerative colitis. Scand J Gastroenterol 18:217-233, 1983.
63. Persson S, Danielsson D. On the occurrence of serum antibodies to bacteroides fragilis and serogroups of E. coli in patients with Crohn's disease. Scand J Infect Dis 19(Suppl):61-67, 1984.
64. + B-cells in Crohn's disease. Gut 34:1698-1704, 1993.
65. Pironi L, Miglioli M, Ruggeri MA, Dallasta MA, Ornigotti L, Valpiani D, Barbara L. Effect of non-steroidal anti-inflammatory drugs (NSAID) on intestinal permeability in first degree relatives of patients with Crohn's disease. Gastroenterology 102:A679, 1992.
66. Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology 110:1395-1403, 1996.
67. Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, Smethurst P, DeLacey G, Gumpel MJ, Levi AJ. Nonsteroidal anti-inflammatory drug-induced intestinal inflammation in humans. Gastroenterology 93:480-489, 1987.
68. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 327:749-754, 1992.
69. Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levis AJ. The effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small bowel. Gut 27:1292-1297, 1986.
70. Bjarnason I, Fehilly B, Smethurst P, Menzies IS, Levi AJ. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut 32:257-277, 1991.
71. Bjarnason I, Williams P, Smethurst P, Peters TJ, Levis AJ. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on permeability of the human small intestine. Gut 27:1292-1297, 1986.
72. Onderdonk AB, Franklin ML, Cisneros RL. Production of experimental ulcerative colitis in genotobiotic guinea pigs with a simplified microflora. Infect Immun 32:225-231, 1982.
73. Kaufman HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 107:513-516, 1987.
74. Bjarnason I, Peters TJ. Intestinal permeability, non-steroidal antiinflammatory drug enteropathy and inflammatory bowel disease: An overview. Gut Festschrift 30:22, 1989.
75. Marin ML, Greenstein AJ, Geller SA, Gordon RE, Aufses AH Jr. A freeze fracture study of Crohn's disease of the terminal ileum: changes in epithelial tight junction organization. Am J Gastroenterol 78:537-547, 1983.
76. Dvorak AM, Connel AB, Dickerson GR. Crohn's disease: electron microscopic studies. Ann Int Med 14:259-306, 1979.
77. Hawker PC, McKay JS, Turnberg LA. Electrolyte transport across colonic mucosa from patients with inflammatory bowel disease. Gastroenterology 79:508-511, 1980.
78. Blaser MJ, Miller RA, Lacher J, Singleton JW. Patients with active Crohn's disease have elevated serum antibodies to antigens of several enteric bacterial pathogens. Gastroenterology 87:888-894, 1984.
79. Teahon K, Smethurst P, Pearson M, Levi AJ, Bjarnason I. The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. Gastroenterology 101:84-89, 1991.
80. O'Morain C, Segal AW, Levi AJ. Elemental diets in treatment of acute Crohn's disease. Br Med J 281:1173-1175, 1980.
81. Allen U, Jones V. Comparison of total parenteral nutrition and elemental diet in induction of remission of Crohn's disease. Dig Dis Sci 32:100-108, 1986.
82. James SP, Strober W, Quinn TC, Danovitch SH. Crohn's disease. New concepts of pathogenesis and current approaches to treatment. Dig Dis Sci 32:1297-1310, 1987.
83. Kirsner JB, Shorter RG. Recent developments in non specific inflammatory bowel disease. N Engl J Med 306:837-848, 1982.
84. O'Morain C, Segal AW, Levi AJ. Elemental diet as primary treatment of acute Crohn's disease: A controlled trial. Br Med J 288:1859-1852, 1984.
85. Ma TY, Hollander D, Katz KD, Krugliak P. Crohn's disease and NSAID enteropathy. Gastroenterology 99:1190-1192, 1990.
86. Inca RD, Leo VD, Martines OM, Mancin O, Lecis PE, Giancon G, Sturniolo GC, Naccaratto R. Permeability of sugars can be helpful in predicting disease activity in Crohn's disease. Gastroenterology 102:A616, 1992.
87. Ito K, Hiwatashi N, Kinouchi Y, Yamazaki H, Toyota T. Improvement of abnormal intestinal permeability in active Crohn's disease by an elemental diet. Gastroenterology 102:A641, 1992.